Rchr
J-GLOBAL ID:201901016503272287   Update date: Nov. 12, 2024

YOSHIKAWA Masahiro

ヨシカワ マサヒロ | YOSHIKAWA Masahiro
Affiliation and department:
Research theme for competitive and other funds  (3):
  • 2015 - 2018 Development of novel kidney regeneration therapy using iPS cell-derived kidney tissue stem cells
  • 2011 - 2015 New cell therapy for kidney disease using human kidney derived iPS cells
  • 2007 - 2008 Investigation of a new promising therapeutic for renal diseases by chromatin remodeling.
Papers (11):
  • Masahiro Yoshikawa, Kensuke Asaba. CCN3/NOV as a potential therapeutic target for diverticular disease: A proteome-wide Mendelian randomization study. Medicine (Baltimore). 2024. 103. 45. e40467
  • Masahiro Yoshikawa, Kensuke Asaba, Tomohiro Nakayama. Prioritization of nasal polyp associated genes by integrating GWAS and eQTL summary data. Frontiers in Genetics. 2023. 14. 1195213
  • Masahiro Yoshikawa, Kensuke Asaba, Tomohiro Nakayama. Estimating causal effects of genetically predicted type 2 diabetes on COVID-19 in the East Asian population. Frontiers in Endocrinology. 2022. 13. 1014882
  • Masahiro Yoshikawa, Kensuke Asaba, Tomohiro Nakayama. Causal effect of atrial fibrillation/flutter on chronic kidney disease: A bidirectional two-sample Mendelian randomization study. PLOS ONE. 2021. 16. 12. e0261020-e0261020
  • Masahiro Yoshikawa, Kensuke Asaba, Tomohiro Nakayama. Estimating causal effects of atherogenic lipid-related traits on COVID-19 susceptibility and severity using a two-sample Mendelian randomization approach. BMC Medical Genomics. 2021. 14. 1. 269
more...
MISC (11):
more...
Education (3):
  • 1995 - 1999 The University of Tokyo Faculty of Medicine
  • 1993 - 1995 The University of Tokyo College of Arts and Sciences Natural Sciences III
  • 1989 - 1992 Musashi High School
Professional career (1):
  • M.D., Ph.D. (The University of Tokyo)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page